Study of NT219 in combination with gemcitabine for the treatment of advanced pancreatic cancer
Phase of Trial: Phase I/II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs NT 219 (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; First in man
- 01 Nov 2017 According to a Kitov Pharmaceuticals media release, an IND submission is expected in the first half of 2019.
- 16 Aug 2017 According to a Kitov Pharmaceuticals media release, the company expects to initiate the clinical trial in 2018.
- 17 Jan 2017 New trial record